InSysBio announces the upcoming workshop on Heta at Quantitative Systems Pharmacology Conference (QSPC 2026). The worksop will be held at Golden Tulip & Tulip Inn Leiden Centre, Leiden, the Netherlands on April 7, 2026, 1 PM – 5 PM.
This workshop introduces an engineering-oriented approach to quantitative systems pharmacology (QSP) modeling using the Heta language and its associated tools. The session focuses on how structured, modular, and process-based model descriptions can improve transparency, reuse, and reproducibility compared to traditional monolithic ODE-based workflows. Participants will be introduced to the core concepts of the Heta language, including process-based model formulation, modularization, and alternative model representations, with an emphasis on how these ideas support scalable QSP workflows rather than on detailed syntax or implementation.
The workshop demonstrates how Heta models are used in practice: from model specification to translation into standard formats and execution with different simulation tools. The session includes guided demonstrations of model conversion using the Heta compiler, basic simulation workflows with HetaSimulator, and an overview of a typical Heta project structure. Short, optional hands-on segments are included for participants who wish to follow along, while others may simply observe the demonstrations. The workshop is intended as an accessible entry point for researchers interested in engineering-style QSP workflows and evaluating whether such an approach fits their existing modeling practice.
What You Will Learn
Who Should Attend
The workshop is free of charge.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio's cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | September 2020 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
|
6
| |
|
7
|
8
|
9
1.
09 Sep 2020 14:59
InSysBio to update its Cytocon DB to version 1.2.6.7
InSysBio announces the new version of Cytocon DB 1.2.6.7! Cytocon DB team has reviewed 39 articles to implement the new data. It should be highlighted that the total number of reviewed articles within the Database has already exceeded 515!
|
10
|
11
|
12
|
13
|
|
14
|
15
|
16
1.
16 Sep 2020 14:54
InSysBio to take part in ACoP11
InSysBio announces its participation in Eleventh American Conference on Pharmacometrics (ACoP11) which is to be held in virtual format this year due to COVID-19 spread 9-13 November, 2020. The theme of ACoP11 is “Scaling New Heights.” InSysBio team is going to present 9 posters in frames of the Conference
|
17
|
18
|
19
|
20
|
|
21
|
22
|
23
1.
23 Sep 2020 10:26
InSysBio announces its collaboration with Genmab
The new partnership strives to evaluate the efficacy of a new oncology therapy – GEN1042 (DuoBody®-CD40x4-1BB)
[Moscow, Russia; Princeton, New Jersey, U.S. – 23.09.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with Genmab, an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
|
24
|
25
|
26
|
27
|
|
28
|
29
|
30
| ||||